# First month for just ₹1: how Flabs, a small Indian lab software company, tripled its site ranking in one quarter · Web

> Source: https://stringers.io/en/web/web_flabslis.com.html (Stringers / 什么值得做, generated 2026-11-08)
> Stringers answers one question every day: what small product can one or two people build in a few months and actually make money from. Numbers come from 15 databases we collect daily, each with source and date.
> For agents: these verdicts and the underlying databases (verified revenue, App Store / Google Play charts, ad libraries, GitHub, Product Hunt…) are queryable live over MCP — tools today / hot / products / directions / direction / data. Setup: https://github.com/komako-workshop/stringers (the user logs in at stringers.io → "配置 agent" to get a personal URL). Site index: https://stringers.io/llms.txt

> In mid-2026 it cut its entry price to ₹1, covered a full month, and even helped migrate customer data. It also let medical reps and distributors sell it for a permanent 20% commission. Each lab signed brings staff and patients back to its domain, so traffic grows with the number of clients.

[Web](https://stringers.io/en/web/index.md) · 11-6 written

Flabs LIMS(flabslis.com) · flabslis.com

# First month for just ₹1: how Flabs, a small Indian lab software company, tripled its site ranking in one quarter

**What it is** Cloud management software for small street-level pathology labs in India: booking, barcode labels, instrument integration, reports, and sending results to patients over WhatsApp, starting at ₹500 a month.

**Why it took off** In mid-2026 it cut its entry price to ₹1 for a full month, with help migrating data included, and gave pharma reps and distributors a permanent 20% commission to sell it for them. Each lab signed brought its staff and patients back to its domain, so traffic grew with the client count.

**C** **How you could apply it** Don't copy Indian lab software, the market is already crowded. Instead, take the playbook of ₹1 first month + hands-on data migration + permanent commissions for people in the industry + linking end-user activity back to your own domain, and move it to another country and another fragmented local small-business industry.

Grade C: the playbook is clear and worth studying, but the product's market, Indian lab software, is already in a price war. Flabs just raised money, and Labsmart and CrelioHealth are both watching it. Instrument integration, compliance, and on-site data migration need people and industry relationships, which makes it a poor bet for a small team to chase directly. What people are saying

Global rank 214k · 90 days ago 740k

Flabs is lab software built by a small company founded in 2023 in Noida, India. It sells to street-level pathology labs: booking, barcode labels, instrument integration, reports, and sending results to patients over WhatsApp, from ₹500 a month (about $6). In summer 2026, it changed the homepage's "5-day free trial" to "₹1 for one month, we'll help migrate your data," and offered everyone who could bring in a lab a permanent 20% commission. Over the next three months, its domain's global website ranking went from 740k to 210k. This piece covers what it is, where the traffic came from, who is competing with it, and whether this playbook is worth moving to another industry or country.

### The homepage line that changed

In Jun 2026 8, flabslis.com's homepage headline read "5 Days Free Trial," with 2,000+ labs listed as users. By Jul 11 (per web archive), the headline had changed to "Try for ₹1," the lab count was 2,500+, and a new page called Flabs Lite had appeared.

那个页面的大字是:「Run your entire lab for just ₹1 this month.」(这个月只花 ₹1,把你整个化验室跑起来。)下面三步:付 ₹1 注册;用满 30 天,「迁移数据、培训员工、给真实病人开单」;喜欢再续,₹500/月起,「不会自动扣费」。常见问题里有一句最要紧:「我们的团队帮你迁移现有的化验室数据、配好报告格式,让你用真实的日常工作来评估,而不是演示数据。」

For a lab switching software, the hard part has never been the monthly fee. It's the switch itself: thousands of old patient records, reference ranges for hundreds of test items, report templates with the lab's own letterhead and doctor's signature, and the front-desk staff who just learned the workflow. A 5-day free trial doesn't even get through one billing cycle. ₹1 for a month, plus someone who comes to help with the migration, means the vendor is also paying the cost of switching for the customer.

The website now says 3,000+ labs (self-reported). From the 2,000+ figure at the time of the funding announcement earlier this year, that's roughly 8 months and up by more than half.

### What it is, and where the traffic lands

Flabs is run by Diagnoshuttle, founded by Yash Chaudhary and a few IIT Roorkee alumni, who started in 2023. In February 2026, it raised a $1.2M seed round led by Indian early-stage fund India Quotient.

The product is a web back office plus a mobile app: patients check in and get billed, samples are tagged with barcodes, it connects to 20 brands of hematology and biochemistry analyzers, results flow into the system automatically, doctors review them and issue reports, each report carries a QR code, and it's sent to the patient's phone via WhatsApp. It also handles referring-doctor commission tracking, a home-draw phlebotomist app, quality control, multi-branch support, AI report interpretation, and voice-dictated radiology reports.

Its traffic is interesting because it's the product itself growing, not the marketing site.

|  | Metric | Sources |
|---|---|---|
| Global website rank | 7-30 #740k → 8-27 #290k → 9-10 #215k, then flat around #214k for the next two months | Tranco rank, as of 11-05 |
| Chrome real-user global tiers | 2026 5: top 500k bucket in June; moved into the top 100k in July | Chrome User Experience Report |
| India buckets | Stayed in the top 50k bucket from May through September | Same as above |
| Android app "Flabs LIMS" | About 13.4k installs, +640 in the last 7 days, #115 in India's free Medical chart | Google Play, early November |
| Labs using it | 2,000+ (2026-02) → 2,500+ (2026-07) → 3,000+ (now) | Funding reports, web archives, and the website are all self-reported by the company. |

Chrome data shows which subdomain gets the most visits, and the answer is always lab.flabslis.com: the back office where lab staff log in every day, not the marketing blog with 425 posts. The same domain also hosts records.flabslis.com, where patients enter their phone number, receive an OTP, and can view and download their past reports.

So what this growth curve means: every lab signed up adds a few staff who keep the back office open all day, plus dozens or hundreds of patients a day tapping a WhatsApp link or scanning a QR code to pick up their reports. A B2B software product sold to a few thousand small shops is getting consumer-grade traffic.

Rankings lag by 1–2 weeks, and Chrome data stepped up in July, so the real jump likely happened around 6–July, which matches the timing of the ₹1 price change. Rankings have been flat since September, suggesting one step up so far, with no second acceleration yet.

### Where users come from

Ranked by volume:

1. **₹1 first-month migration help** (confirmed). As noted above, this is their biggest change this year, and it lines up with the traffic jump.

2. **20% lifetime commission partner program** (confirmed). The partner-program page is blunt: "Anyone can become a Flabs partner... earn 20% of every payment, for as long as the lab keeps paying." No entry bar, no cap, paid monthly on the 1th to a bank account. There's a dedicated partner app where you enter the lab's name, owner's phone, and city, and in a minute you can "attach this lab to your account." The targets named are pharma reps ("already visiting labs and clinics every day"), lab consultants, reagent and equipment distributors, and lab owners. Small Indian labs have long been connected through exactly these people, and Flabs has turned that offline network into a commission-driven sales force. Promo videos with referral codes show up on Facebook.

3. **The report itself is an ad** (mechanism confirmed, how many customers it brings is inference). Every report is printed with a Flabs QR code, so patients and ordering doctors keep returning to the domain. Other lab owners in the same city see the report in a patient's hand and see Flabs.

4. **Search and comparison pages** (confirmed to exist, traffic share unknown). The site has 425 medical explainers and industry articles (how to read a CBC, thyroid reference ranges, "how much does it cost to open a pathology lab in India"), 10 city landing pages (Delhi, Mumbai...), 4 "Flabs vs X" comparison pages, and a kidney function calculator. It is also listed on software review sites like Capterra and SourceForge.

5. **YouTube and Instagram** : short demo videos and doctor testimonial clips in English and Hindi, with modest reach. One of the five-star App Store reviews is signed dhwajgupta, the same name as co-founder Dhwaj Gupta.

I found no evidence of paid ads, but Google Search ads are the most likely channel for this category. Not finding evidence isn't the same as none running.

### Where the money comes from

Just subscription fees: from ₹500/month, monthly billing only. In the ₹1 first month there's no auto-renewal, so the customer has to decide whether to continue. Revenue and paying lab counts aren't public. Of the 3,000+ labs, we can't see how many pay or what the retention rate is.

Rough math: if half of 3,000 labs pay, at an average ₹1,000/month, that's about ₹180M a year, roughly $2M by estimate. This is a volume game with very low prices, and a 20% lifetime commission means that for every lab they bring in, the company permanently gives up a fifth of that revenue.

### Who it's competing with

The Indian lab software market is highly fragmented, and prices have already been pushed to the floor:

| Competitors | Scale | How Flabs compares |
|---|---|---|
| Labsmart | Claims 3,000+ labs, global rank around #93k, more than twice Flabs' traffic | Leader at the same price point, from ₹417/month, 5-day trial, positioned as "built for small labs, simple to use" |
| CrelioHealth (formerly LiveHealth) | Established, backed by Nexus, also active in the US market | Skews toward chains and mid-size labs, sells through a sales process |
| Drlogy | Claims 51k labs, clinics and doctors, rank declining | A do-everything healthcare platform where labs are just one piece |
| MyLabReport, LabQuick, SoftEazy, PingMeDoc and a long list of others | Mostly no visible traffic | Monthly fees of ₹199–₹2,999, some cheaper than Flabs |
| Old locally installed software, paper and Excel | Most small labs in India | The people Flabs is actually fighting for |

The clearest sign of where it stands is how competitors respond. Labsmart published "Flabs vs Labsmart," arguing that Flabs' target customer is unclear and that it is complicated for small labs, and specifically noting that contacting their support often leads you to WhatsApp. CrelioHealth published "CrelioHealth vs Flabs," positioning itself for "independent labs with tight budgets, single locations, and stable workflows." PingMeDoc, Odireca and DoraysLIS have each written a comparison too. A three-year-old company has become the one everyone in this category feels they need to compare against. That's good for Flabs, but bad news for anyone trying to follow: every player in this market is watching it.

No one has copied the ₹1 first-month offer yet.

### What it actually wins on

On features, Flabs is "priced like a small vendor, featured like a mid-to-high-end product": bidirectional instrument integration, quality control, compliance workflows, multi-location support, AI report interpretation. But "cheap and complete" can't be owned in India. Labsmart also claims 3,000 labs and has more traffic.

What actually made it take off are three things that have little to do with code:

- **The entry offer** : ₹1 plus manual data migration, so customers run a full month on real business instead of clicking through a demo for 5 days;

- **The distribution** : a lifetime 20% commission, so the people who already visit labs every day sell it for them;

- **把终端用户放在自己域名下** :病人取报告、医生看报告都回到 flabslis.com,B2B 产品拿到了 B2C 的曝光。

The AI features are more of a story told during fundraising and on comparison pages.

### If it were you

**Verdict** : C. Worth learning from, not worth copying directly. If you build an Indian lab software product, you face a dozen rivals already in a price war, a freshly funded Flabs, and a Labsmart with twice its traffic. Instrument integration, compliance, and on-site migration each need people and time, and no one or two developers can close that gap by writing code. What's worth taking away is the go-to-market playbook, not the product.

**Who it suits** : a small team with connections in a fragmented local industry, who know a group of pharmacy, clinic, driving school, dental, vet or school owners, or who have worked as a salesperson or agent in that industry. Ideally in a country where software hasn't yet covered the market. Flabs itself gets scattered traffic from the Philippines, Mexico and Indonesia, suggesting labs there are looking for this kind of tool.

**Who it doesn't suit** : people who only want to write code and won't make calls or visit sites; anyone hoping to win customers through SEO and organic app store traffic (Flabs has 425 articles, but they aren't the main driver); anyone wanting to enter Indian pathology labs (already crowded).

**How to build it** : pick an industry with lots of small local businesses that still run on paper or old desktop software, where the business has to hand end users a "document" each day (a report, prescription, transcript, warranty card). Start with a web back office plus a mobile app, and get the three most painful things right: billing, producing the document, and sending it to end users through WhatsApp or whatever chat app locals use most. Put a QR code on the document that links back to your own domain.

**How to acquire customers** : skip the free trial and do what Flabs did: a symbolic ₹1 for a full month, and you migrate their old data for them. Give lifetime commissions to people already serving the industry, like distributors, reps, consultants and peer owners, and build a simple referral app so they can submit leads anytime. Programmatic city and comparison pages are fine to publish, but don't expect them to carry the growth.

**Timing** : no holiday deadline here, the pressure comes from competitors. The ₹1 first-month offer is currently unique, and once Labsmart and others follow, it stops being novel in India. In other countries and industries, whoever locks in local relationships first wins, so build distribution as early as possible.

**Signs you've misread it** : ① Flabs' ranking falls back below #2027k in early 500, meaning the ₹1 offer mostly brought people who leave after one month and the funnel doesn't convert; ② Labsmart or CrelioHealth launch a ₹1 first-month offer and Flabs' growth stalls, meaning it only won a one-time price novelty, not a playbook; ③ the partner program quietly cuts commissions or switches to first-year only, meaning the 20% lifetime commission doesn't add up, so recalculate before copying.

### Data and sources

- Website rank: Tranco daily ranks (2026-07-30 to 11-05); Chrome User Experience Report monthly buckets (2026-05 to 09).

- App: Google Play "Flabs LIMS – Pathology App" (early November); App Store India reviews page (11-06).

- Website: flabslis.com, /flabs-lite, /partner-program (read 11-06); homepage snapshots from web archives 2026-03-11, 06-08, 07-11.

- Funding: India Quotient announcements on X and LinkedIn, Venture Intelligence coverage (2026-02), Tracxn.

- Competitors: labsmartlis.com's "Flabs vs Labsmart", creliohealth.com's "CrelioHealth vs Flabs", pingmedoc.com, odireca.com, dorayslis.com comparison articles, and each vendor's pricing page (11-06).

- Lab counts and features are self-reported by the company. Revenue and paying-lab counts are not public. Anything marked "inferred" or "estimated" is our inference or estimate.

[Website ↗](https://flabslis.com)

**Research notes: competitor table, acquisition evidence, full research report**

Competitors

| Name | Where | Launched | Scale | How it differs from this one |
|---|---|---|---|---|
| Labsmart(labsmartlis.com) | Web | About 2020 years ago (unverified) | Claims 3,000+ labs; Tranco ~93k, CrUX India top 5,000 | The leader in the same price band, with more than twice Flabs's traffic. From ₹417/month, 5-day trial. Flabs has fuller instrument integration, QC, multi-branch and AI features, and lowers the barrier with ₹1 for one month plus help migrating data. |
| LiveHealth / CrelioHealth | Web | Around 2014 (unverified) | Backed by Nexus; livehealth.solutions Tranco ~80k | Aimed at mid-to-large and chain labs and overseas markets. Priced high, sold through sales teams. Flabs targets small labs with low prices and self-serve signup. |
| Drlogy | Web | Not verified | Claims 51,000+ labs/hospitals/doctors; Tranco fell from 200k to 300k | A broad medical platform where labs are one piece with shallow features. Flabs's comparison page goes after what it lacks: instrument integration, QC, B2B |
| ITDOSE, Healthray, PathoGold, MyLabReport, LabQuick, SoftEazy, ClinikPe, PingMeDoc, and others | Web | All different | Lots of small vendors, priced ₹199–₹2,999 a month | A very fragmented market where the price war has already bottomed out. Flabs isn't the cheapest. Its edge is the fullest feature set plus the lowest entry barrier. |
| Local / offline lab software and paper | Other | Has been around all along | Most small labs in India | Flabs mainly poaches from here: cloud access, reports sent via WhatsApp, mobile app |

Where users come from

- **Verified** **₹1 for one month plus help migrating data (lowering the price barrier)** : Wayback: 2026-06-08 homepage still said "5 Days Free Trial", 2,000+; 2026-07-11 changed to "Try for ₹1" and launched /flabs-lite, now writes 2,500+. Matches the step-up in CrUX global in July.

- **Verified** **Partner program, agent commissions** : /partner-program is open to anyone. Partners earn 20% of every payment from labs they bring, permanently. There's a partner app, aimed at pharma reps, distributors and consultants. Promo videos on Facebook carry referral codes like ref=P369.

- **Verified** **SEO and comparison pages** : The sitemap has 463 URLs: 425 medical and industry blog posts, 10 city pages, 4 vs comparison pages, an eGFR calculator, and llms.txt. Badges are listed on review sites like SourceForge, Slashdot and Capterra.

- **Verified** **Product-driven distribution (patient report portal, doctor side)** : records.flabslis.com lets patients pull reports with their phone number, and reports carry a QR code and a WhatsApp link. CrUX's best-ranked source is lab.flabslis.com, not the marketing site.

- **Verified** **YouTube, Instagram, Reddit content** : The @flabs-in channel has short English and Hindi demo videos. r/pathology has organic promo posts. Volumes are small.

- Inferred **Paid ads** : Our Meta, Google and TikTok ad libraries show no match. That doesn't mean they aren't spending.

- **Verified** **Funding and startup media** : 2026-02 India Quotient led a $1.2M round to expand sales and support and opened a Bangalore office. The media coverage itself brings no customers.

## Flabs (flabslis.com): the cloud LIS for Indian pathology labs, and why its traffic rank rose 3.5x in one quarter

### One line

Flabs is a cloud lab information system (LIS/LIMS) built by Diagnoshuttle Pvt Ltd of Noida (founded 2023 years ago by four IIT Roorkee alumni), sold to small and mid-sized pathology labs and imaging centers in India. It covers billing, sample barcodes, instrument integration, report generation, WhatsApp report delivery, doctor referral commissions, a sample-collector app, plus AI interpretation and voice-to-report. Monthly plans start at ₹500.

**Bottom line** : the traffic rank climb comes mostly from real, sustained product usage, not web marketing bringing in visitors. The strongest source in CrUX has always been `lab.flabslis.com`, the portal lab staff log into every day to get their work done. The other is `records.flabslis.com`, where patients pick up their reports with a phone number, and it sits on the same domain. Each new lab signed brings in daily staff usage plus a few hundred patients collecting reports. The inflection in growth lines up with the 2026 February seed round and the 2026 6–July switch from a "5-day free trial" to "₹1 for one month."

### 1. Data

| Metric | Value | Source |
|---|---|---|
| Tranco rank | 2026-07-30 740,844 → 08-13 548,799 → 08-27 294,711 → 09-10 215,304, then flat at 21.4–218k for the next two months. 11-05 is 214,470. | traffic.rank_day |
| CrUX global tier | 2026-05, before 06: top 500k → from 2026-07 top 100k (07, 08, 09 all in that band); best_origin has been lab.flabslis.com throughout | traffic.crux_domain |
| CrUX India bucket | From 2026-05 to 09 it stayed in the top 50k (can't tell whether it moved within that bucket). There are also sporadic buckets in the Philippines, Mexico and Indonesia. | traffic.crux_domain |
| Google Play "Flabs LIMS – Pathology App" | Launched 2024-11-09; 13,415 installs, +7 in the last 640 days (about 100 a day); #115 in India's free Medical chart | googleplay.app_profile,2026-11-07 |
| iOS | A same-named app exists (id6736873615), but no data in our database | App Store page |
| Lab count (company-reported) | 2026-02 funding news 2,000+; website said 2026-06-08+ at one point, 2,000 2026-07-11+ later, now 2,500+ 3,000 | Venture Intelligence, The Unicorn Magazine, Wayback snapshots, company website |
| Funding | 2026-02 seed round of $1.2M led by India Quotient, previously backed by 100X.VC and IIT Roorkee TIDES | India Quotient's X / LinkedIn posts, Venture Intelligence |

The timeline needs a correction: Tranco's big jump landed between mid-August and early September, but Tranco is a 30-day rolling average and lags real traffic by 1–2 weeks. CrUX global entered the top 100k as early as July. So the real traffic step-up happened around **2026 6–July** . Tranco has been flat since September, which suggests one step-up followed by no further acceleration.

### 2. What it is and where its traffic lands

- `flabslis.com`: marketing site, built on Next.js. The sitemap has 463 URLs, including 425 blog posts on topics like CBC, kidney function, thyroid reference ranges, "how much a CT machine costs in India" and "how to open a pathology lab". There are also 10 city pages (pathology-lab-software-delhi/mumbai/…), 4 comparison pages (vs Labsmart / Drlogy / CrelioHealth / ITDOSE), an eGFR calculator, and llms.txt.

- `lab.flabslis.com`: the SaaS portal lab staff log into, and the ₹1 signup entry point. **It has consistently been CrUX's best source.**

- `records.flabslis.com`: patients enter their +91 phone number, receive an OTP, and view and download their own reports ("My Medical History"). Reports carry a QR code and are also sent via WhatsApp, so patients and referring doctors click back to this domain.

- `developer.flabslis.com`: public API documentation.

- App: about 13k installs on Play, used by lab owners and staff on their phones. The doctor referral app and sample-collector app are separate products.

**Traffic is mostly on the web app, and mostly from product usage** : staff work in the web backend all day, and patients arrive from WhatsApp or the QR code to pull reports. Blog SEO brings some long-tail visitors, but the best CrUX source is not the main site, so the blog isn't the driver. The recall reasoning worried that "part of this may be SEO pages rather than product traffic". Origin-level data mostly rules that out.

### III. Competitors

| Competitors | Form | Scale and launch timing | How it differs from Flabs |
|---|---|---|---|
| Labsmart(labsmartlis.com) | Web SaaS | Claims 3,000+ labs; Google rating from 4.9,600+ reviews; Tranco ~93k (very stable), CrUX India top 5,000, global top 50k | The leader for small and mid-sized pathology labs in India, with roughly 2x or more Flabs's traffic. From ₹417/month, 5-day trial. Flabs is fuller on heavy features like instrument integration, QC, multi-branch and AI, at a similar price. |
| LiveHealth / CrelioHealth (livehealth.solutions, creliohealth.com) | Web SaaS (also sells into the US) | Established; backed by Nexus Venture. livehealth.solutions Tranco ~80k, creliohealth.com ~588k | Aimed at mid-to-large and chain labs and overseas markets. Priced high, sold through sales processes. Flabs goes for low-price self-serve and small labs. |
| Drlogy(drlogy.com) | Web + app, medical all-in-one platform | Claims 51,000+ labs/hospitals/doctors; Tranco fell from 200k to 303k | A sprawling platform where labs are only one part. Flabs's comparison page targets what it lacks: instrument integration, sample intake, QC, B2B |
| ITDOSE, Healthray, PathoGold, Labmate, MyLabReport (₹399), LabQuick (₹299), SoftEazy (₹199), ClinikPe (₹2,999), PingMeDoc (₹1,999), and others | Web / local software | A long tail of small vendors, mostly with no visible traffic rank | A very fragmented market where the price war already reached ₹200–₹500 a month. Flabs's pricing isn't remarkably cheap. Its edge is the lowest free-entry barrier (₹1 for a full month, plus data migration help) combined with the fullest feature set. |
| Local / offline software, paper | Other | Most small labs in India | Flabs mainly poaches from here. Its site says: "Why choose Flabs over Offline Path Lab Software" |
| Big international vendors (Orchard, Epic Beaker, NovoPath, etc.) | big-company products | a price small Indian labs can't afford | not the same market |

**Someone is already treating Flabs as a rival to beat** : PingMeDoc published a "PingMeDoc vs Flabs" comparison page describing Flabs as "a pathology LIS with mobile apps, an AI report suite and a ₹1 month-long trial". So peers in this small industry already see Flabs as the benchmark. No one has copied the ₹1 first-month offer yet.

### 4. Where users come from (growth levers)

1. **Cut the entry price to ₹1 (confirmed)** . Wayback snapshots show the homepage headline still read "5 Days Free Trial" with "2,000+ Labs" at 2026-03-11 and 06-08. By 2026-07-11 it changed to "Try for ₹1", and a /flabs-lite page appeared (₹1 for a full 30 days, no auto-billing, the team helps migrate data and configure report formats, then ₹500/month onward), with the lab count changed to 2,500+. The timing lines up with CrUX's global tier moving up in July. The biggest cost of switching lab software is migrating data and training staff, and a 5-day trial can't even get through one billing cycle. A month for ₹1 plus hands-on migration help removes the switching cost too.

2. **A 20% lifetime-revenue-share partner program (confirmed)** . /partner-program is open to anyone. Partners earn 20% of every payment from the labs they bring in, for as long as those labs pay. Payouts are monthly, and there's a dedicated partner app. It's explicitly aimed at medical reps, lab consultants, reagent and instrument distributors, and lab owners. Promo videos on Facebook carry referral links like `lab.flabslis.com/signup?ref=P369`. Small Indian labs are already tied together through medical reps and distributors, so this turns those offline channels into a commission-based sales force.

3. **Programmatic SEO and comparison pages (confirmed to exist, traffic volume unknown)** : 425 blog posts, 10 city pages, 4 "Flabs vs X" comparison pages, an eGFR calculator, and llms.txt. Badges are also listed on software review sites like SourceForge, Slashdot, TopBusinessSoftware, and Capterra.

4. **Built-in distribution from the product (inferred from how it works; the mechanism itself is confirmed)** : every report carries a Flabs QR code and WhatsApp link, so patients and referring doctors keep coming back to flabslis.com. This is the main driver of the Tranco and CrUX rank gains, and it also exposes Flabs to other labs in the same city (inferred).

5. **Content and social** : a YouTube channel @flabs-in with English and Hindi demo shorts and doctor testimonial videos; Instagram @flabs.official; LinkedIn; and organic promo posts on r/pathology on Reddit ("A lab software to democratise pathology"). Volume is small.

6. **Ads** : the Meta, Google, and TikTok ad libraries we check don't show Flabs domains (only the Play library matches). Not finding them doesn't mean they aren't running ads, so this is marked unverified.

7. **Funding and press** : the 2026-02 seed round got covered by startup outlets like Venture Intelligence, The Unicorn Magazine, Tracxn, and YourStory. These are investor-facing outlets and don't bring in lab customers. The money went to hiring, and they opened a Bengaluru HSR office in addition to Noida to expand sales and support.

### 5. Why it broke out

- **Real B2B usage stepped up** : the best CrUX source is the lab portal, not the marketing site. The lab count went from 2026-02 to 2,000+ and is now 3,000+, roughly half that growth in 8 months (self-reported by the company).

- **Changed the pricing entry point in mid-2026** : from a 5-day free trial to ₹1 for a month plus data migration help. The timing matches CrUX's global tier jumping from the top 500k to the top 100k.

- **The partner program turns offline lab-network relationships in India into a channel** : 20% lifetime revenue share gives medical reps and distributors a reason to push it every day.

- **Network effects drive traffic** : the patient report portal and the doctor referral side both sit on the same domain, so each lab signed adds to that domain's traffic in proportion to its patient count.

- **The timing of the money was right** : the 2026-02 $1.2M round was just enough to add sales, support, and features (AI interpretation, voice-to-radiology reports, quality control, multi-branch).

### VI. Differentiation

In India's small-lab price band, Flabs's edge is that **its price is close to the cheapest small vendors (₹500/month), but its feature set is close to mid-to-high-end products like CrelioHealth** (bidirectional instrument integration with 20+ brands, Westgard QC, NABL compliance workflows, a B2B portal, multi-branch, ABHA and EkaCare integration, AI interpretation and voice-to-report), plus **the ₹1 first month and data migration help** , the lowest-friction way in. That explains part of why it's growing, but not all of it. "Cheap and complete" can't be owned alone in India's crowded LIS market: Labsmart also claims 3,000+ labs, and it still gets more than twice Flabs's traffic. What really separated the growth is **the entry method (₹1 plus migration) and the distribution method (20% lifetime share)** . That's the playbook, not the AI features; AI is more of a selling point and a fundraising story.

### 7. How many people know about it

Word of mouth stays inside a small circle. The funding was covered by Indian startup outlets (Venture Intelligence, The Unicorn Magazine, YourStory, Tracxn), and India Quotient posted the announcement on X and LinkedIn. There's no related discussion in local X content, and revenue isn't public (no TrustMRR listing, and founders haven't shared revenue). Outside the Indian health SaaS circle almost nobody knows about it, but within this industry peers are already writing "vs Flabs" pages.

### 8. What others can borrow

- Fragmented, relationship-driven vertical B2B industries (labs, clinics, pharmacies, driving schools, primary schools): **₹1 first month plus hands-on migration help** gets customers through a full billing cycle better than a free trial does. A **20% lifetime revenue share** turns people already working the industry's customer base (medical reps, distributors) into part-time salespeople.

- Put **what end consumers need (viewing reports, QR verification) on your own domain** , and a B2B product can pick up B2C-level traffic and brand exposure.

- City pages, comparison pages, long-tail medical education content, software review site badges, and llms.txt: low-cost SEO and AI search coverage at scale.

### 9. What I'm still unsure about

- 3,000+ labs is self-reported. How many pay, and retention, are unknown. How many of the ₹1 first-month users convert to paid is also unknown.

- Unknown whether they run Google Search ads (the most likely channel in this category). Our ad libraries don't match.

- Tranco has been flat since September. Whether the ₹1-driven growth is a one-time bump or sustained will show up in the 10 and November CrUX data.

- CrUX tiers in the Philippines, Mexico, and Indonesia, plus overseas user reviews like Summit Medical Diagnostics, suggest it may be starting to expand abroad. Scale is unclear.

### Sources

- Local databases: traffic.rank_day / crux_domain / product_domain; googleplay.app_profile / app_day (2026-11-07 queries)

- Official site: [flabslis.com](https://flabslis.com), /flabs-lite, /partner-program, /compare/flabs-vs-drlogy, /investor-relations, sitemap.xml, records.flabslis.com

- Wayback: web.archive.org/web/20260311003103, 20260608060314, 20260711015207 /[flabslis.com/](https://flabslis.com/)

- Funding: [x.com/IndiaQuotient/status/2027250244174647394](https://x.com/IndiaQuotient/status/2027250244174647394); [news.ventureintelligence.com/private-equity/pathology-focuse…](https://news.ventureintelligence.com/private-equity/pathology-focused-operating-system-flabs-raises-$1.2-m-led-by-indiaquotient); The Unicorn Magazine LinkedIn post

- Competitors: labsmartlis.com, pingmedoc.com/pathology-lab-software (includes vs Flabs), drlogy.com, Tracxn CrelioHealth, labquick.in, softeazy.in, mylabreport.in, clinikpe.com

- Social: youtube.com/@flabs-in, reddit.com/r/pathology/comments/1ni908d, Facebook video with referral code P369

This article was written by AI from public data and the data we collect daily. Numbers are sourced, and inferences are labeled.